Pfizer Plans Biologics Clinical Manufacturing Plant In Andover, Massachusetts
06/17/2016
“The expansion of Pfizer’s presence in Andover will provide state-of-the-art manufacturing to help bring new medicines and vaccines to the patients we serve,” said John Ludwig, Senior Vice President, BioTherapeutics Pharmaceutical Sciences in Pfizer R&D. “Andover is a crucial part of our global footprint for both clinical and commercial manufacturing, and we believe it provides an attractive location for growth in the coming years.”
Earlier this year, Andover officials approved $2.9 million in tax incentives for the Pfizer project. The town’s Board of Selectmen, Planning Board and Finance Committee all recommended the five-year Tax-Increment Financing plan.
“Pfizer’s decision to expand their campus in Andover speaks to the Commonwealth’s continued global leadership in biopharma and our administration’s support of the growing advanced manufacturing sector,” said Massachusetts’ Lieutenant Governor Karyn Polito. “We are pleased to have Pfizer operating in Andover, Boston and Cambridge and look forward to their ongoing contributions to the Massachusetts’s economy and wellbeing of our citizens.”
Project Announcements
United Arab Emirates-Based Hotpack Plans Edison, New Jersey, Manufacturing Operations
05/12/2025
SSAB Expands Axis, Alabama, Production Operations
05/12/2025
Carnival Corporation Plans Miami, Florida, Headquarters Operations
05/12/2025
Merck Animal Health Expands De Soto, Kansas, Manufacturing Operations
05/12/2025
Oxford Technologies Plans Bay County, Florida, Manufacturing Operations
05/12/2025
PPG Plans Shelby, North Carolina, Manufacturing Operations
05/12/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
The Location Economics of Advanced Nuclear
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Navigating the new era of SCIF construction
Q1 2025